Eli Lilly and Company remains months behind Eisai Co., Ltd./Biogen, Inc. in bringing an anti-amyloid antibody to market, but with Phase III TRAILBLAZER-ALZ 2 trial results on 3 May showing a 35% slowing in clinical decline for early Alzheimer’s patients treated with donanemab, Lilly plans to file for US Food and Drug Administration during the second quarter of 2023. The data appear to show greater efficacy than seen with Eisai/Biogen’s Leqembi (lecanemab) last year, although with greater risks.
Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent
Full Approval Sought After Accelerated Nod Denied Previously
The company’s anti-amyloid antibody succeeded in Phase III with efficacy at least on par with Eisai/Biogen’s Leqembi, but with ARIA-related deaths unseen with the rival therapy.
More from Clinical Trials
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from R&D
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.